Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5mg-10mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

Clinical Pharmacokinetics

Volumn 49, Issue 12, 2010, Pages 829-840

  Retlich, Silke ^a   Duval, Vincent ^b   Ring, Arne ^b   Staab, Alexander ^b   Httner, Silke ^b   Jungnik, Arvid ^c   Jaehde, Ulrich ^a   Dugi, Klaus A ^b   Graefe Mody, Ulrike ^b  

^a UNIVERSITY OF BONN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c PHAROS GmbH   (Germany)

Author keywords

Antihyperglycaemics, pharmacodynamics; Antihyperglycaemics, pharmacokinetics; Bioavailability; Dipeptidyl peptidase inhibitors, pharmacodynamics; Dipeptidyl peptidase inhibitors, pharmacokinetics; Linagliptin, pharmacodynamics; Linagliptin, pharmacokinetics; Pharmacokinetic modelling; Pharmacokinetic pharmacodynamic relationships; Population pharmacokinetics; Research and development.

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; DIPEPTIDYL PEPTIDASE IV; LINAGLIPTIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEADY STATE; URINARY EXCRETION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN BINDING; PURINES; QUINAZOLINES; SINGLE-BLIND METHOD; TABLETS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 78249262065     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11536620-000000000-00000     Document Type: Article

References (30)

1. EckhardtM, Langkopf E,Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but- 2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007 Dec; 50 (26): 6450-3
2. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005 Oct; 54 (10): 2988-94
3. Elliott RM,Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993 Jul; 138 (1): 159-66
4. Nauck MA, Bartels E, Orskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993 Apr; 76 (4): 912-7
5. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993 Aug; 36 (8): 741-4 (Pubitemid 23218642)
6. Nauck MA, Sauerwald A, Ritzel R, et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998 Nov; 21 (11): 1925-31
7. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 Dec; 2 (8571): 1300-4
8. Hüttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008 Oct; 48 (10): 1171-8
9. Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009 Aug; 11 (8): 786-94
10. Fuchs H, Tillement JP,Urien S, et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009 Jan; 61 (1): 55-62
11. Bialer M,WuWH, Look ZM, et al. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol 1987 Apr; 56 (1): 21-32
12. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007 Sep; 46 (9): 787-802
13. Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet 2002 Mar; 41 (3): 225-34
14. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)- 7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor,has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008 Apr; 325 (1): 175-82
15. Picard-Hagen N, Gayrard V, Alvinerie M, et al. A nonlabeled method to evaluate cortisol production rate by modelling plasma CBG-free cortisol disposition. Am J Physiol Endocrinol Metab 2001 Nov; 281 (5): E946-56
16. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. PharmRes 2005Oct; 22 (10): 1589-96
17. King JN, Maurer M, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. J Vet Pharmacol Ther 2003 Jun; 26 (3): 213-24
18. Toutain PL, Lefebvre HP, King JN. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 2000 Mar; 292 (3): 1087-93
19. Gibiansky L.Weighting in NONMEM. In: NONMEM users network [discussion list on the Internet]. 2003 May 2 [online]. Available from URL: http://www.cognigencorp.com/nonmem/nm/98jun022003.html [Accessed 2010 Oct 6]
20. Karlsson M. When to do transformation of data? [2 posts]. In: NONMEM users network [discussion list on the Internet]. 2002 April 29 [online].Available from URL: http://www.cognigencorp.com/nonmem/nm/99apr232002. html [Accessed 2010 Oct 6]
21. Cordero OJ, Ayude D, Nogueira M, et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000 Nov; 83 (9): 1139-46
22. Cuchacovich M, Gatica H, Pizzo SV, et al. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 2001 Nov-Dec; 19 (6): 673-80
23. Retlich S, Duval V, Graefe-Mody U, et al. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010 Aug; 50 (8): 873-85
24. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005 Jun; 48 (6): 1168-72
25. Ryskjaer J,DeaconCF, CarrRD, et al. Plasmadipeptidyl peptidase-IVactivity in patients with type-2 diabetesmellitus correlates positively withHbAlc levels, but is not acutely affected by food intake.Eur J Endocrinol 2006 Sep; 155 (3): 485-93
26. Center for Drug Evaluation and Research, US FDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations.Rockville (MD): FDA, 2003Mar [online].Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070124.pdf [Accessed 2010 Oct 6]
27. Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004 Dec; 27 (6): 455-66
28. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. JClin Endocrinol Metab 2006 Nov; 91 (11): 4612-9
29. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008 May; 10 (5): 376-86
30. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008 Mar; 30 (3): 499-512